Adjuvance Receives $1.47 Million from NIH for COVID-19 Vaccine

Adjuvance Technologies has received $1.47 million from the NIH’s National Institutes for Allergy and Infectious Diseases (NIAID) to help develop a COVID-19 vaccine using the company’s adjuvant.

The funding will be used to test Adjuvance’s saponin-based adjuvant TQL1055 with NIAID’s SARS-CoV-2 antigen.

Derived from the bark of a South American tree, saponin-based adjuvants have been used in multiple vaccines for many years.